Age-Related Macular Degeneration Bibliography

AMD Review/Classification

Ferris FL III, Wilkinson CP, Bird A, et al; Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration [published online January 16, 2013]. Ophthalmology. 2013;120(4):844-851. doi:10.1016/j.ophtha.2012.10.036.

Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738. doi:10.1016/S0140-6736(12)60282-7.

Olsen TW, Adelman RA, Flaxel CJ, et al; American Academy of Ophthalmology. Age-related macular degeneration preferred practice pattern. https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015. Published January 2015. Accessed March 14, 2018.

AMD Epidemiology

Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010;10:31. doi:10.1186/1471-2415-10-31.

Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114(2):253–262. doi:10.1016/j.ophtha.2006.10.040.

AMD Genetics

DeAngelis MM, Owen LA, Morrison MA, et al. Genetics of age-related macular degeneration. Hum Mol Genet. 2017;26(R1):R45-R50. doi:10.1093/hmg/ddx343.

Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together [published online April 16, 2014]. Annu Rev Genomics Hum Genet. 2014;15:151-171. doi:10.1146/annurev-genom-090413-025610.

Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration [published online March 10, 2005]. Science. 2005;308(5720):385–389. doi:10.1126/science.1109557.

AMD and Depression

Casten RJ, Rovner BW. Update on depression and age-related macular degeneration. Curr Opin Ophthalmol. 2013;24(3):239-243. doi:10.1097/ICU.0b013e32835f8e55.

AREDS /AREDS2 Trial

Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417–1436. doi:10.1001/archopht.119.10.1417.

Aronow ME, Chew EY. Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions. Curr Opin Ophthalmol. 2014;25(3):186-190. doi:10.1097/ICU.0000000000000046.

Chew EY, Clemons TE, SanGiovanni JP, et al; Age-Related Eye Disease Study 2 (AREDS2) Research Group. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report no. 3. JAMA Ophthalmol. 2014;132(2):142-149. doi:10.1001/jamaophthalmol.2013.7376.

Brolucizumab

Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG, HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017.

Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, Schmidt-Erfurth U, Holz FG. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2021 Jan;128(1):89-99. doi: 10.1016/j.ophtha.2020.06.028.

Wykoff CC, Matsumoto H, Barakat MR, Karcher H, Lozama A, Mayhook A, Oshagbemi OA, Zorina O, Hassan TS, Khanani AM, Heier JS. RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence. Retina. 2023 Jul 1;43(7):1051-1063. doi: 10.1097/IAE.0000000000003769. Epub 2023 Jun 16. PMID: 36893438; PMCID: PMC10278563.

Eylea HD

Wykoff, Charles C, Brown, David M, Reed, Kimberly, Berliner, Alyson J, Gerstenblith, Adam T, Breazna, Aurora, Abraham, Fein, Jordana G, Chu, Karen W, Clark, W Lloyd, Leal, Sergio, Schmelter, Thomas, Hirshberg, Boaz, Yancopoulos, George D, Vitti, Robert; CANDELA Study Investigators. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmology. 2023 Sep 1;141(9):834-842. doi: 10.1001/jamaophthalmol.2023.2421.

Faricimab

Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. PMID: 35085502.

Macular Photocoagulation Study

Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol.1991;109(8):1109-1114. doi:10.1001/archopht.1991.01080080069030.

Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1982;100(6):912–918. doi:10.1001/archopht.1982.01030030920003.

Photodynamic Therapy/ Visudyne

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol. 2001;119(2):198–207. doi:10-1001/pubs.Ophthalmol.-ISSN-0003-9950-119-2-ecs00156.

Ranibizumab

Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481.

Ranibizumab vs Bevicizumab (CATT Trial) and Safety

CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration [published online April 28, 2011]. N Engl J Med. 2011;364(20):1897–1908. doi:10.1056/NEJMoa1102673.

Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;(9):1-87. doi:10.1002/14651858.CD011230.pub2.

Aflibercept

Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration [published online October 17, 2012]. Ophthalmology. 2012;119(12):2537-2548. doi:10.1016/j.ophtha.2012.09.006.

Sarwar S. Clearfield E, Soliman MK, et al. Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2016;2:CD011346. doi:10.1002/14651858.CD011346.pub2.

Stem Cells

Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies [published online October 15, 2014]. Lancet. 2014;385(9967):509-516. doi:10.1016/S0140-6736(14)61376-3.

Zarbin M, Sugino I, Townes-Anderson E. Concise Review: Update on Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration. Stem Cells Transl Med. 2019. doi:10.1002/sctm.18-0282.

Imaging

Borrelli E, Sarraf D, Freund KB, Sadda SR. OCT angiography and evaluation of the choroid and choroidal vascular disorders [published online July 27, 2018]. Prog Retin Eye Res. 2018;67:30-55. doi:10.1016/j.preteyeres.2018.07.002.

Emerging New Treatments

Khurana RN, Kunimoto D, Yoon YH, Wykoff CC, Chang A, Maturi RK, Agostini H, Souied E, Chow DR, Lotery AJ, Ohji M, Bandello F, Belfort R Jr, Li XY, Jiao J, Le G, Kim K, Schmidt W, Hashad Y; CEDAR and SEQUOIA Study Groups. Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Nov 19:S0161-6420(20)31109-X. doi: 10.1016/j.ophtha.2020.11.017. Epub ahead of print. PMID: 33221326.

Holekamp NM, Campochiaro PA, Chang M, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C, All Archway Investigators. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2022 Mar;129(3):295-307. doi: 10.1016/j.ophtha.2021.09.016.

Heier, Jeffrey S, Lad, Eleonora M, Holz, Frank G, Rosenfeld, Philip J, Guymer, Robyn H, Boyer, David, Grossi, Federico, Baumal, Caroline R, Korobelnik, Jean-Francois, Slakter, Jason S, Waheed, Nadia K, Metlapally, Ravi, Pearce, Ian, Steinle, Nathan, Francone, Anibal A, Hu, Allen, Lally, David R, Deschatelets, Pascal, Francois, Cedric, Bliss, Caleb, Staurenghi, Giovanni, Monés, Jordi, Singh, Rishi P, Ribeiro, Ramiro, Wykoff, Charles C. OAKS and DERBY study investigators. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Clinical Trial, Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9.

Khanani, Arshad M, Patel, Sunil S, Staurenghi, Giovanni, Tadayoni, Ramin, Danzig, Carl J, Eichenbaum, David A, Hsu, Jason, Wykoff, Charles C, Heier, Jeffrey S, Lally, David R, Monés, Jordi, Nielsen, Jared S, Sheth, Veeral S, Kaiser, Peter K, Clark, Julie, Zhu, Liansheng, Patel, Hersh, Tang, Justin, Desai, Dhaval, Glenn, J Jaffe; GATHER2 trial investigators. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8.

Jackson, Timothy L, Slakter, Jason, Buyse, Marc, Wang, Kun, Dugel, Pravin U, Wykoff, Charles C, Boyer, David S, Gerometta, Michael, Baldwin, Megan E, Price, Clare F; Opthea Study Group Investigators. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2023 Jun;130(6):588-597. doi: 10.1016/j.ophtha.2023.02.001. Epub 2023 Feb 6.

Updated March 2025